Connect BiopharmaCNTB
About: Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
Employees: 81
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
27% more funds holding
Funds holding: 11 [Q3] → 14 (+3) [Q4]
3% more capital invested
Capital invested by funds: $4.23M [Q3] → $4.37M (+$143K) [Q4]
0.43% more ownership
Funds ownership: 5.33% [Q3] → 5.76% (+0.43%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Emily Bodnar 18% 1-year accuracy 29 / 161 met price target | 1,267%upside $8 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion
Based on 4 articles about CNTB published over the past 30 days









